Accelerate Dx Begins $45M Rights Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Accelerate Diagnostics said after the close of the market on Monday that it has commenced a $45 million rights offering to fund the firm's product commercialization efforts.

The Tucson, Ariz.-based company is distributing at no charge to the holders of its common stock as of 5:00 PM EDT, March 14, 2014, .063921 non-transferable subscription rights for each share of stock owned.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.